This study was aimed to investigate the effect of weight loss by bariatric
surgery on the level of anti-Mullerian hormone (AMH) in morbidly obese female
patients with or without polycystic ovary syndrome (PCOS). This prospective
study includes 70 females, obese, and fertile patients of reproductive age. All
patients were evaluated to determine the changes in weight, body mass index
(BMI), serum AMH, and other biochemical parameters at the end of six months. The
mean levels of the preop and postop AMH were
1.66±0.87 ng/ml and
5.99±1.39 ng/ml in the PCOS group;
1.35±0.76 ng/ml and
6.23±1.47 ng/ml in the non-PCOS group, respectively. The
postop AMH levels were significantly higher than the preop levels for both
groups (p<0.001). There were significant differences in the level of
glucose, low-density lipoprotein (LDL), high-density lipoprotein (HDL),
triglyceride, total cholesterol, hemoglobin A1c, HOMA-IR, insulin between preop
and postop 6th month. A negative correlation was found between postop AMH and
body weight in all patients (r=–0.337, p=0.031). Postop
AMH levels were negatively correlated with postop BMI levels in the non-PCOS
patient group (r=–0.408, p=0.043). No significant
difference was observed between the PCOS and non-PCOS groups in terms of all the
parameters examined. In conclusion, our study suggests that the significantly
increased AMH levels by losing weight with bariatric surgery in patients with
morbid obesity with and without PCOS may indicate the improvement of
fertilization potential. It could be considered when evaluating fertility in
patients with morbid obesity.
Essential thrombocythemia (ET) is an entity of classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), characterized by thrombocytosis with megakaryocytic hyperplasia and thrombocytes are increased with abnormal functions. Discovery of the protein tyrosine kinase JAK2 V617F allele contributed to better understanding of the pathogenetic mechanisms of MPNs. Acquired single point mutation in the JAK2 V617F was determined approximately 50-60 % of patients with ET. In this study we aimed to investigate the relationship between JAK2 V617F gene mutation, hematologic, biochemical markers and the complications in the ET patients. A total of 268 patients diagnosed with ET and 219 of those studied for JAK2 gene mutation were followed at the hematology clinics of three major hospitals between 2008 and 2013 were screened retrospectively. Laboratory, clinical and hematologic parameters were compared for JAK2 V617F positive and JAK2 V617F negative patients with ET. 102 (46 %) patients were positive with the JAK2 V617F mutation. The complications were observed in 61 (28 %) patients and 38 (62 %) of them had JAK2 V617F mutation. The levels of white blood cells, neutrophil, basophil, red blood cells, hemoglobin, hematocrit, mean platelet volume, thrombocytes, eosinophil; urea, creatinine were significantly different in patients with the JAK2 V617F mutation (P < 0.05). Presence of the JAK2 V617F mutation supports the diagnosis of ET. It would be useful to investigate the JAK2 V617F mutation and the hematologic and biochemical markers at diagnosis with respect to consider the risk of developing complications and to take the precautions against these complications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.